- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Drs Rebecca Borgert and Jim Rebello Discuss What Could Persuade Payers to Use Biosimilars
Rebecca Borgert, PharmD, BCOP, and Jim Rebello, PharmD, from Magellan Rx Management, discussed what evidence they believe could persuade payers to include biosimilars as preferred formulary products.
Rebecca Borgert, PharmD, BCOP, is the senior director of oncology clinical strategy and innovation and Jim Rebello, PharmD, is the vice president of formulary strategies at Magellan Rx Management.
Transcript:
What sort of evidence might help persuade payers to put more biosimilars on formulary and give them preferred status?
Borgert: That’s what we’re hoping our case study will show when we present at AMCP 2021 on Friday. We feel like we have a pretty persuasive argument that the payers that do not prefer biosimilars and instead have them just on the formulary at parity with the reference products are definitely leaving money on the table. I think if anything will motivate payers to rethink their strategy around biosimilars, I think that will be it.
Rebello: Yeah, totally agree. Case studies and data showing both the uptake and the actual savings instead of theoretical savings—having real-world savings—I think it’s great. Also, showing that the level of provider uptake and embracement that we haven’t had, because of the proactiveness and the level of collaboration, a lot of provider pushback. There has been a lot of noise. So, I think sharing all of that information with payers that maybe haven’t gone down this road yet should encourage more use, not just in oncology, but in any future biosimilar category. We know there’s more coming, probably every year for who knows how long.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
